MedPath

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Phase 2
Completed
Conditions
Bipolar I Depression
Interventions
Drug: Placebo
Registration Number
NCT00812058
Lead Sponsor
Repligen Corporation
Brief Summary

The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
180
Inclusion Criteria
  • Bipolar I Disorder, most recent episode depressed
  • History of 2 or more manic or mixed episodes, at least one of which required pharmacologic treatment for manic symptoms
Exclusion Criteria
  • Current manic, hypomanic or mixed episode
  • Rapid cycling bipolar disorder (4 or more mood episodes in the last year)
  • Dementia or any other Axis I diagnosis (besides bipolar I) that requires treatment
  • Alcohol or drug dependence within 6 months; alcohol or drug abuse within 3 months
  • Positive urine drug test for amphetamines, cocaine metabolites, opiates and/or phencyclidine(PCP)
  • Axis II diagnosis likely to interfere with study compliance
  • Serious suicidal or homicidal risk
  • Sensitivity to any of the drug ingredients, including lactose
  • Women who are pregnant, breast feeding or refuse to use adequate birth control
  • Current seizure disorder
  • Current episode of depression is longer than 1 year

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboOral placebo taken twice daily for 8 weeks
RG2417RG2417Oral RG2417 taken twice daily for 8 weeks
Primary Outcome Measures
NameTimeMethod
MADRS ScoreBaseline and weekly for 8 weeks
Secondary Outcome Measures
NameTimeMethod
Safety Findings (includes AE frequency, YMRS Score and CSSR-S Score)Baseline, 8 weeks of study drug dosing and one follow up visit at 4 weeks
CGI-BP-SBaseline and weekly for 8 weeks

Trial Locations

Locations (36)

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Western Psychiatric Institute Clinic

🇺🇸

Pittsburg, Pennsylvania, United States

Vanderbilt University School of Medicine

🇺🇸

Nashville, Tennessee, United States

University of Texas, Houston Medical Center

🇺🇸

Houston, Texas, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Birmingham Psychiatry Pharmaceutical Studies, Inc.

🇺🇸

Birmingham, Alabama, United States

Carman Research

🇺🇸

Smyrna, Georgia, United States

Valle Vista Health System

🇺🇸

Greenwood, Indiana, United States

K&S Professional Research Services

🇺🇸

Little Rock, Arkansas, United States

Atlanta Center for Medical Research

🇺🇸

Atlanta, Georgia, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Oregon Center for Clinical Investigations, Inc.

🇺🇸

Portland, Oregon, United States

Louisiana State University Health Sciences Center

🇺🇸

Shreveport, Louisiana, United States

Behavioral Clinical Research

🇺🇸

North Miami, Florida, United States

Affiliated Research Institute

🇺🇸

San Diego, California, United States

Johns Hopkins School of Medicine

🇺🇸

Baltimore, Maryland, United States

Midwest Clinical Research Center

🇺🇸

Dayton, Ohio, United States

Behavioral Medical Research of States Island

🇺🇸

Staten Island, New York, United States

IPS Research Company

🇺🇸

Oklahoma City, Oklahoma, United States

CNS Healthcare

🇺🇸

Memphis, Tennessee, United States

Lincoln Research

🇺🇸

Lincoln, Rhode Island, United States

FutureSearch Trials of Dallas

🇺🇸

Dallas, Texas, United States

Northwest Clinical Research Center

🇺🇸

Bellevue, Washington, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

University of Virginia

🇺🇸

Charlottesville, Virginia, United States

Richard H. Weisler, MD, PA and Associates

🇺🇸

Raleigh, North Carolina, United States

Yale University

🇺🇸

New Haven, Connecticut, United States

Clinical Neuroscience Solution, Inc.

🇺🇸

Orlando, Florida, United States

Unvieristy of North Carolina - Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

FutureSearch Trials of Austin

🇺🇸

Austin, Texas, United States

University of South Florida College of Medicine

🇺🇸

Tampa, Florida, United States

Mayo Clinic Department of Pscyhiatry & Psychology

🇺🇸

Rochester, Minnesota, United States

Ralph H. Johnson VA Medical Center

🇺🇸

Charleston, South Carolina, United States

Dean Foundation

🇺🇸

Middleton, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath